Alpha Capital's Strategic Role with CD8 Technology
Alpha Capital Corp has recently been appointed as the exclusive financial advisor to CD8 Technology Services, LLC. This partnership marks a significant step as they seek to secure funding, potentially up to $50 million, aimed at enhancing the development and manufacturing of biologic products specifically for cell therapy.
Transforming Cell Therapy Manufacturing
Through this funding initiative, CD8 Technology aims to establish a state-of-the-art facility focusing on Good Manufacturing Practice (GMP) capabilities. This facility will fast-track the process of manufacturing biologic products, which is crucial for companies aiming to develop effective therapies. By removing barriers to capital and reducing the timeline associated with setting up GMP capabilities, CD8 Technology intends to serve its clients more efficiently.
The Vision for Biologic Contract Manufacturing
Upon completion, CD8 Technology will stand out as one of the few independent biologic contract manufacturing organizations in the country. They are committed to prioritizing partnerships with key clients such as Tevogen Bio, ensuring that their manufacturing needs for off-the-shelf, genetically unmodified T-cell therapeutics are fully met. Tevogen is projected to achieve significant revenue through this collaboration, which emphasizes the importance of this funding initiative.
Alpha Capital's Expertise
Alpha Capital brings a wealth of experience in the life sciences field, which will serve as a tremendous asset to CD8 Technology. The firm will be involved in various aspects of the financing process, providing services that include capital structuring, valuation, and a diverse set of financing options tailored to the specific needs of CD8 Technology. The representatives at Alpha have expressed their enthusiasm, stating their commitment to delivering exceptional advisory services and leveraging their extensive industry expertise to meet the objectives of CD8 Technology.
About Alpha Capital
Alpha Capital Corp serves as a strategic consulting firm alongside its identity as a boutique merchant bank. With a robust background in manufacturing and IT industries, the firm specializes in areas such as merchant banking, mergers and acquisitions, and capital raising. Their focus lies predominantly within the healthcare and hospitality sectors, aiming to provide high-quality support to organizations seeking to grow and innovate within these fields.
Frequently Asked Questions
What role does Alpha Capital play for CD8 Technology?
Alpha Capital has been appointed as the exclusive financial advisor to CD8 Technology, assisting in securing funding for biologic product manufacturing.
How much funding is CD8 Technology aiming to secure?
CD8 Technology is looking to secure up to $50 million to develop their manufacturing capabilities.
What is the significance of the GMP capabilities?
Good Manufacturing Practice (GMP) capabilities will enable faster and more efficient manufacturing processes crucial for cell therapy products.
Who will benefit from CD8 Technology's new facility?
The facility will primarily benefit clients like Tevogen Bio, which relies on CD8 Technology for its T-cell therapeutic manufacturing needs.
What industries does Alpha Capital focus on?
Alpha Capital primarily focuses on the healthcare and hospitality sectors, providing specialized advisory services tailored to these industries.
